drugset / Trial / NCT02979366

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02979366

Phase 1 Completed 38 enrolled Servier ADIR, a Servier Group company · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.

Timeline

Start
2017-03-15
Primary completion
2020-05-11
Completion
2020-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MIK665 Unknown 50 mg Intravenous